Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q1 2025 (March 31)7holders −2
2new positions
4sold out
$1.24avg. 13F price*
At the end of Q1 2025, 7 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, down 2 from Q4 2024. 2 opened new positions and 4 sold out. The largest holders were BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($5.7M), Bank of New York Mellon Corp ($1.2M) and Nomura Holdings Inc. ($413K).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q4 2024 → Q1 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 2 | $573K |
| Exits | 4 | $6.9M |
All 13F filers, Q4 2024 → Q1 2025: 655,122 shares bought and 6,509,500 shares sold, net −5,854,378 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 7 holders
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.02% | No change | 4,950,000 | $5.7M |
| Bank of New York Mellon Corp | 0.00% | Add +100.0% | 1,000,000 | $1.2M |
| Nomura Holdings Inc. | 0.00% | New | 1,528 | $413K |
| Sei Investments Co. | 0.00% | Add +153.5% | 251,000 | $289K |
| Loomis Sayles & Co. L P | 0.00% | New | 594 | $160K |
| Oppenheimer Asset Management Inc. | 0.00% | Add +1.3% | 79,000 | $91K |
| Stephens Inc. | 0.00% | No change | 22,000 | $25K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.